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of Life in a Series of 103 Patients With
Hyperimmunoglobulinemia D Syndrome
Jeroen C. H. van der Hilst, Evelien J. Bodar, Karyl S. Barron, Joost Frenkel, Joost P. H. Drenth,
Jos W. M. van der Meer, Anna Simon, and the International HIDS Study Group*
Abstract: The hyperimmunoglobulinemia D and periodic fever
syndrome (HIDS), one of the autoinflammatory syndromes, is
caused by mutations in the gene coding for mevalonate kinase
(MVK). We conducted the current study to assess the genetic,
laboratory, and clinical features as well as the complications and
course of disease in patients with genetically confirmed HIDS. In
addition, we studied the quality of life and course of life in a
selection of patients. Follow-up data were obtained by a question-
naire sent to all physicians of patients in the International HIDS
Database. In addition, we assessed the course of life and quality of
life in Dutch patients aged 916 years using validated quality of life
instruments.
Data were obtained from 103 patients from 18 different
countries. The median age of first attack was 6 months (range,
0Y120 mo), with a median period of 9.9 years from onset of disease
to diagnosis. The most frequent symptoms that accompanied
attacks of fever were lymphadenopathy, abdominal pain, arthralgia,
diarrhea, vomiting, skin lesions, and aphthous ulcers. Amyloidosis
was a severe but infrequent complication (2.9%). The median
serum IgD level was 400 U/mL. IgD levels were normal in 22% of
patients. The 4 most prevalent mutations (V377I, I268T, H20P/N,
P167L) accounted for 71.5% of mutations found. The frequency of
attacks decreased with the patient_s increasing age, although 50%
of patients over the age of 20 years still had 6 or more attacks per
year. Many drugs have been tried in HIDS. Some patients re-
sponded to high-dose prednisone (24.4% response). Anakinra and
etanercept can also be effective (33.3% response). Quality of life
was determined in a subgroup of patients (n = 28). Social func-
tioning, general health perception, and vitality were significantly
lower in patients with HIDS than in controls, as were autonomy and
social development. In addition, HIDS had an adverse impact on
educational achievements and employment status. In conclusion,
HIDS is an early-onset disease that is accompanied by an array of
inflammatory symptoms. Although the frequency of attacks
decreases during the patient_s life, many patients continue to have
frequent attacks. HIDS impairs several aspects of quality of life.
(Medicine 2008;87:301Y310)
Abbreviations: FMF = familial Mediterranean fever, HIDS = hyper-
immunoglobulinemia D and periodic fever syndrome, MKD = meval-
onate kinase deficiency, MVA = mevalonic aciduria, MVK =
mevalonate kinase, RAND-36 = RAND-36 Health Survey, TAAQoL =
TNOAZL Adult Quality of Life questionnaire, TRAPS = tumor necrosis
factor-1 receptor-associated periodic syndrome.
INTRODUCTION
The hyperimmunoglobulinemia D and periodic feversyndrome (HIDS) is one of the autoinflammatory fever
syndromes. The autoinflammatory syndromes form a group
of hereditary disorders characterized by lifelong recurrent
inflammatory attacks, with fever as the most prominent
symptom, usually accompanied by other phenomena such as
arthritis, abdominal pain, diarrhea, lymphadenopathy, and
skin lesions14. Inflammatory attacks are invariably associ-
ated with a vigorous acute-phase response and strongly el-
evated C-reactive protein and serum amyloid A37. The
autoinflammatory syndromes include at least 6 different
inherited disorders. They can be distinguished based on
mode of inheritance and genetic basis. Familial Mediterra-
nean fever (FMF), and HIDS are autosomal recessively
inherited. On the other hand, tumor necrosis factor-1
receptor-associated periodic syndrome (TRAPS), and the
cryopyrin-associated periodic syndromes (CAPS)38 are dom-
inantly inherited. Research into the autoinflammatory dis-
orders has been boosted by the elucidation of the molecular
origins. HIDS is caused by mutations in the gene that
encodes mevalonate kinase (MVK)13,19. This is an enzyme
in the isoprenoid pathway in which cholesterol is produced,
in addition to a number of nonsterol isoprenoids. Isoprenoids
are essential compounds in diverse cellular functions and
include farnesyl, geranyl, and ubiquinone20. Mutations
in MVK lead to 2 distinct syndromes: HIDS as a mild
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phenotype, and mevalonic aciduria (MVA) as a more severe
phenotype; collectively they are sometimes designated
Bmevalonate kinase deficiency[ (or MKD). Although the
incriminating gene was discovered in 1999, the exact mech-
anism of inflammation in HIDS has not been elucidated. An
increased production of interleukin-1" by mononuclear cells
has been suggested as a central mechanism in the inflamma-
tory phenotype of HIDS12,16. Recently, it has been shown
that a deficiency in geranylgeranyl, one of the isoprenoids,
leads to increased production of interleukin-1" by human
mononuclear cells, providing further evidence for a central
role of interleukin-1" in the pathogenesis of HIDS22,24. Also,
it has been shown that lymphocytes from HIDS patients
show a defective apoptosis. This may lead to an unbridled
inflammatory response after a minor stimulus, as an expla-
nation for the inflammatory phenotype of HIDS4.
The first patients with HIDS were described in 198439.
In 1994, the International HIDS Study Group was estab-
lished to collect data on patients with this rare disease. In an
article in this journal 14 years ago, before the discovery of
the causative gene mutations, we presented preliminary data
on 50 patients who, on clinical grounds, were classified as
having HIDS11. Apart from the fact that our previous study
necessarily included patients diagnosed based on only clin-
ical criteria, it also left a number of questions unanswered.
The prevalence of amyloidosis or the development of other
complications was unknown, as was the possible effect on
mortality. Further, the general clinical impression was that
the frequency of attacks abates with time, but that has never
been substantiated. Also, the effect of this syndrome on sev-
eral dimensions of the quality of life has not been studied
previously.
We conducted the current study to characterize a large
international cohort of patients with mutation-positive HIDS
in detail, including assessing the genetic, laboratory, and
clinical features, but most especially assessing the preva-
lence of complications, survival, and progression of disease.
In addition, we studied the quality of life and course of life
in a selection of patients.
PATIENTS AND METHODS
In the International HIDS Database (www.hids.net),
we collect data about patients with suspected and confirmed
HIDS. Data are submitted by the patient’s physician. With
the submission of a new patient to the registry, physicians
are asked about clinical features, inflammatory markers,
serum immunoglobulin concentrations, and results of muta-
tional analysis. This database does not contain data on
patients with the more severe phenotype of MVA. Although
somewhat arbitrary, we considered patients with any of the
following as having MVA: severe psychomotor retardation,
progressive cerebellar ataxia, typical dysmorphic features,
and progressive visual impairment18. A total of 244 patients
was submitted up to January 2007. In 47 patients, genetic
testing did not reveal mutations in MVK. In 71 patients,
genetic testing was not performed or data about testing
were unavailable. Some genetic laboratories tested only for
the most common mutations. A total of 126 patients with
mutation-positive HIDS, defined as recurrent attacks of fever
and at least 1 mutation detected in the MVK gene, were
eligible for this study. All registered physicians of these
patients received an additional questionnaire about clinical
features, complications, course of disease, and response to
therapy, and, where applicable, were asked to supply missing
information. Patients were included when follow-up data
were available up until January 2007 or until their death.
Quality of Life and Course of Life Assessment
For the assessment of quality of life and course of life
we included only Dutch patients 916 years of age who had
the ability to understand the standardized questionnaires in
the Dutch language. The patients were approached by their
treating physician, and after giving informed consent, re-
ceived a letter with an explanation of the study and a ques-
tionnaire booklet. After 1 month a reminder letter and a new
booklet were sent to those who did not respond. The ques-
tionnaire included 3 items:
The Course of Life questionnaire, a Dutch question-
naire, was used to assess the achievement of develop-
mental milestones retrospectively in persons aged 16Y30
years. This questionnaire was developed to investigate the
course of life in persons who have grown up with a chronic
or life-threatening disease compared to peers without a his-
tory of disease17. The validity of the course of life scales
and the test-retest reliability are good17. For the current
study we used 2 scales: development of autonomy and so-
cial development. In addition, the questionnaire measures
sociodemographic outcomes in young adulthood, such as
living situation, education, and employment. Data derived
from a group of 508 Dutch controls were available for
comparison32.
The RAND-36 Health Survey was used to assess the
quality of life and is almost identical to the MOS SF-36. The
RAND-36 is the most commonly used health status measure-
ment for assessing quality of life in the world. It measures
8 different health domains: physical functioning, role limi-
tations due to physical health, social functioning, role limi-
tations due toemotionalproblems,bodilypain,vitality,general
health perception, and mental health. The validity and
reliability of the RAND scales are satisfactory40. Norm data
were available from a sample of 1036 persons41.
Since the RAND-36 does not measure cognitive func-
tioning satisfactorily, we added the cognitive function scale of
the TNOAZL Adult Quality of Life (TAAQoL) questionnaire
to the study. The TAAQoL is a validated, generic health-
related quality of life questionnaire developed by researchers
from TNO and the Leiden University Medical Center. The
cognition scale consists of 4 items; a higher score indicates
better cognitive functioning15. We compared the TAAQoL
cognition score of the HIDS patients with the Dutch norms
provided by Fekkes and colleagues15.
The local ethical committee approved the study design.
Statistical Analysis
The Statistical Package for Social Sciences (SPSS)
Windows version 14.02 was used for all analyses. We used
the chi-square test to evaluate categorical data, and the
Student t-test to compare the mean between groups. We
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performed nonparametric Mann-Whitney U tests to test
group differences in the number of attacks per year and the
Friedman test to test for change of number of attacks dur-
ing life. To adjust for multiple testing, a significance level of
p G 0.01 was used for all tests of quality of life.
RESULTS
Demographic Features
Of the 126 patients with mutation-positive HIDS, 103
patients could be included in this study. Reasons for ex-
clusion included no response from registered physician (n =
17) and loss to follow-up (n = 6). Excluded patients did
not differ from included patients in current age, age of onset,
or IgD concentrations (data not shown). The patients orig-
inated from 18 different countries on 3 different conti-
nents, although the majority of patients were European, or
from European ancestry (Figure 1). The median current age
of patients was 19.0 years (mean, 24.5 yr) with a range of
2Y74 years (Table 1). The median age of onset of symp-
toms was 6 months, ranging from the first week of life to
10 years. Most patients had their first attack within the first
year of life (78.1%); 6 patients had the first symptoms after
the age of 4 years (Figure 2). The diagnosis of HIDS was
made at a mean age of 15.7 years (median, 10.0 yr; range,
G3 moY52 yr). There was a mean delay to diagnosis of
13.9 years (median, 9.9 yr). In recent years the delay in time
to diagnosis has not changed significantly. In patients with
HIDS diagnosed after the year 2000 (n = 50), there was still
a mean delay to diagnosis of 11.7 years (median, 8.4 yr). In
33 patients an alternative diagnosis was made before HIDS
was diagnosed (Table 2).
Clinical Features
Attacks of fever were accompanied by an array of signs
and symptoms (Figure 3). A typical attack of HIDS started
with prodromal symptoms such as malaise and headache,
followed by a rapid rise in temperature, often 940 -C. Cold
chills accompanied fever in two-thirds of patients. Physical
and emotional stress was recognized by many patients as a
precipitating factor. Childhood vaccinations often induced
the first attack; this was reported in 63% of patients.
Lymphadenopathy and Splenomegaly
Lymphadenopathy accompanied attacks in almost 90%
of patients. The enlarged lymph nodes were generally
painful on palpation and were located primarily in the
cervical region. Axillary and inguinal localization occurred
less frequently. Splenomegaly was found in 32.4% of
patients, and all patients who had splenomegaly also had
accompanying lymphadenopathy (Table 3).
Gastrointestinal Symptoms
Abdominal pain, vomiting, and/or diarrhea accompa-
nied attacks in all but 5 patients. Abdominal pain could be
severe and could resemble acute abdomen, tempting the
attending physician to order exploratory surgery. At least 7
patients had surgery for suspected appendicitis. In 6 patients
abdominal adhesions were found on exploratory surgery,
suggesting repeated sterile peritonitis as the cause of abdo-
minal pain.
Articular Symptoms
Arthralgia, a prominent feature of HIDS, was experi-
enced by 83.5% of patients, making it the third most fre-
quent symptom of HIDS after lymphadenopathy and
abdominal pain. Fifty percent of the patients had arthritis,
defined as swollen, tender joints. Information about the
specific joint involved was available in 60 of 86 patients with
arthritis and/or arthralgia (Figure 4). Arthralgia and arthritis
were mainly restricted to large peripheral joints. In the
FIGURE 1. Country of origin of 103 patients with HIDS.
TABLE 1. Demographic Features
Feature
No. of Patients With
Data Available
Current age, median in
yr (range)
19.0 (2Y74) 103
Sex (male:female) 52:51 103
Age at onset, median
in yr (range)
0.5 (0Y10) 96
Follow-up from onset,
median in yr (range)
17.6 (2Y74) 96
FIGURE 2. Distribution of age at onset of symptoms.
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hands, both metacarpophalangeal and proximal interphalan-
geal joints may be affected.
Cutaneous and Mucocutaneous Manifestations
Skin manifestations accompanied attacks of fever in
more than two-thirds of patients. Usually this was a maculo-
papular rash, but urticarial rash, purpura, and erythema no-
dosum have also been reported. Oral aphthous ulcers with or
without accompanying genital ulcerations were reported in
48.5% of patients. That aphthous ulcers can be a very promi-
nent symptom is illustrated by the fact that in 3 patients a
diagnosis of Beh0et disease was made before the diagnosis
of HIDS.
Laboratory Results
All patients had a vigorous acute-phase response dur-
ing attacks, with elevated ESR (median, 76 mm/h), leuko-
cytosis (median, 15,000 per mm3), and C-reactive protein
(median, 163; range, 36Y404 mg/L). Between attacks, some
patients had continuous elevation of inflammation mark-
ers, although much lower than during attacks. An eleva-
tion of serum polyclonal IgD is considered a hallmark of
the disease. The median IgD concentration of the highest
IgD measured in the patients was 400 U/mL (range,
G0.8Y5300 IU/mL). However, an elevated IgD concentration
was not universally present in HIDS patients: in 22% of
patients, the highest concentration of IgD measured was
below the upper limit of normal (G100 IU/mL).
Elevation of serum IgD is frequently accompanied by
elevation of serum IgA. Data about serum IgA concentration
was available for 86 patients. In 55 patients (64%), the IgA
concentration was above the upper limit of normal of 2.6 g/L
(median, 4.05 g/L).
TABLE 2. Incorrect Diagnoses Made Before HIDS Diagnosis
Diagnosis No. of Patients
FMF 13
Adult-onset Still disease 6
JCA 5
Rheumatic fever 3
Chronic infection 3
Beh0et disease 3
Abbreviation: JCA = juvenile chronic arthritis.
FIGURE 3. Clinical features of HIDS.
TABLE 3. Symptoms During Attacks
Symptom % of Patients
Lymphadenopathy 87.4
Abdominal pain 85.4
Arthralgia 83.5
Diarrhea 71.6
Vomiting 70.9
Skin lesions 68.9
Headache 63.3
Cold chills 62.7
Arthritis 55.3
Aphthous ulcers 48.5
Splenomegaly 32.4
Hepatomegaly 21.6
Serositis 18.6
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Genetics
Table 4 shows the most prevalent mutations. The 4
most prevalent mutations accounted for 71.5% of mutations
found. Only 4 patients did not have any of these 4 prevalent
mutations. In 12 patients only 1 mutation was identified.
Seventy-seven patients were compound heterozygote, while
14 patients were homozygote. We compared compound
heterozygotes for V377I, I268T, H20P, P167L, and V377I
homozygotes (n = 11) with patients who did not carry these
mutations. There was no association between these geno-
types and age of onset, symptoms during attacks, and num-
ber of attacks per year (data not shown).
Follow-Up: Course of Disease and
Complications
Frequency of Attacks During Life
We asked physicians to indicate the number of attacks
occurring in their patients. There was a significant decrease
in the frequency of attacks with increasing age (Figure 5),
although no patients had a remission. In the first decade of
life, 44.1% of patients had more than 12 attacks per year.
This decreased to 23.9% in the second decade of life.
After the age of 20 years, 17.8% of patients continued to
FIGURE 4. The location of articular symptoms in HIDS, in-
cluding arthralgia and arthritis. Note that more than 1 joint
is often involved in a single patient.
TABLE 4. Allele Frequencies of MVK Mutations
Mutation Allele Frequency (%)
V377I 50
I268T 14.7
H20P/N 4.4
P167L 2.4
H380R 1.5
R215Q 1.5
W188X 1.5
25 Other mutations and deletions All G1
FIGURE 5. Number of attacks per year in the first decade
of life (A), in the second decade of life (B), and after the
age of 20 years (C), as retrospectively reported by patients_
physicians.
TABLE 5. Medications Tried and Response to Therapy
in HIDS Patients*
No
Response
(n)
Some
Response
(n)
Good
Response
(n)
Prednisone (n = 45) 17 17 11
Colchicine (n = 44) 37 7 0
Statin (n = 18) 12 4 2
Antibiotics (n = 13) 11 2 0
Etanercept (n = 13) 4 5 4
Anakinra (n = 11) 4 3 4
Thalidomide (n = 8) 7 1 0
Cyclosporine (n = 7) 6 1 0
*Patients may have used multiple medications.
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have attacks more than 12 times per year, while 50% of
patients still had more than 6 attacks per year ( p = 0.001).
Thirty-three of 45 patients above the age of 20 years had
fewer attacks after the age of 20 years than in the first
decade of life.
Amyloidosis
Type AA amyloidosis, a frequent complication in the
other autoinflammatory diseases, was reported in 3 patients
(2.9%) who have been described elsewhere27. All 3 patients
had recurrent fevers for more than 20 years before the
manifestation of amyloidosis. No additional cases of am-
yloidosis in HIDS were discovered in the current follow-up
study.
Abdominal Adhesions
Repeated peritonitis, resulting in abdominal adhesions
found during laparotomy, was reported in 10 patients.
Joint Contractures
Joint contractures as a result of arthritis was reported
in 2 siblings aged 13 and 14 years, and in 2 brothers aged 17
and 27 years. None of the other patients manifested any
signs of erosive arthritis.
Mortality
Three patients in the cohort died during the follow-up.
The causes of death did not seem to be associated with HIDS
symptoms or complications. The causes of death were sui-
cide (patient aged 50 yr), cerebral hemorrhage (aged 61 yr),
and pneumococcal sepsis (aged 31 yr).
Therapeutic Interventions
A wide variety of immunomodulatory drugs was
tried to treat and prevent attacks in this cohort of patients
(Table 5). Apart from the drugs listed in the table, the fol-
lowing medications have been tried with limited, if any, suc-
cess: methotrexate, azathioprine, salazopyrine, tacrolimus,
dapsone, intravenous immunoglobulins, montelukast, cimet-
idine, and ranitidine. When prednisone was given in high
dosage at the onset of an attack, a considerable number of
patients experienced a reduction in severity and duration of
attacks (24.4% good response, 37.8% some response). Col-
chicine was ineffective in preventing or treating attacks in
HIDS, in contrast to FMF. In 80% of patients in whom it
was tried (n = 20) the biological agents anakinra and etaner-
cept had at least some response. When anakinra is ineffec-
tive, patients may respond to etanercept, and vice versa.
Quality of Life and Course of Life
Thirty-eight patients were eligible for this study.
Twenty-eight patients returned the quality of life question-
naire (73.7%). Patient characteristics are listed in Table 6.
There was no significant difference between the study
population and other patients from the cohort 916 years of
age concerning prevalence of symptoms, age of onset, and
number of attacks.
Health-Related Quality of Life
The RAND-36 dimensions social functioning, physical
role functioning, general health perception, and vitality were
significantly lower ( p G 0.01) in patients than in the general
TABLE 6. Characteristics of Patients Included in the Quality
of Life Assessment
Median age, yr (range) 34.6 (16.5Y67.5)
Median age at onset, mo 6
Mean disease duration, yr (range) 31.9 (16.3Y65.1)
Male:female (n:n) 15:11
No. of attacks last year (n)
G1 1
1Y6 16
7Y12 6
912 3
FIGURE 6. Comparison of health-related quality of life (RAND-36) in HIDS patients and in Dutch control group. Error bars
represent SEM. *p G 0.01.
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population (Figure 6). Patients who experienced more than
6 attacks in the past year scored significantly lower on the
scales for pain (53.1 T 11.6 vs. 87.3 T 6.5; p G 0.01), physical
role functioning (18.8 T 12.3 vs. 80.8 T 10.3; p = 0.01), and
general health perception (27.5 T 5.1 vs. 47.8 T 5.0; p = 0.01)
than patients with 6 or fewer attacks in the past year. There
was no significant difference on the TAAQoL cognition
scale between HIDS patients and the comparison group
(data not shown).
Course of Life
Autonomy development and social development dur-
ing childhood were significantly lower in patients with HIDS
compared to controls (Table 7). In addition, 45.8% of
patients indicated that their disease delayed their education,
and in 17% this made high school graduation unachievable.
During primary education, 44% had to repeat a year, while
41% of patients repeated a year during high school.
Furthermore, 34.8% of patients reported that their disease
contributed to discharge from their jobs. Currently, 26.6% of
the patients were unemployed, a much higher percentage
than in the general Dutch population (4.0%)7.
DISCUSSION
The current study is, to our knowledge, the largest
series of HIDS patients reported so far and the first to
investigate the progression of disease and the effects of
HIDS on quality of life. Although patients were entered into
the database over a period of 14 years and patients
originated from 18 different countries, we were able to
obtain follow-up data from 81.7% of patients.
One purpose of the present study was to collect new
data on clinical features of HIDS. The frequency of symp-
toms found in this study differs to some extent from the
frequency found in our 1994 report of 50 patients in whom
HIDS had been diagnosed based on purely clinical
groundsVthat is, recurrent fever episodes and persistent
elevation of serum IgD11. In the current study we found
more abdominal pain (85.4% vs. 72%), vomiting (70.9% vs.
56%), and headache (63.3% vs. 52%), while skin lesions
(68.9% vs. 82%) and splenomegaly (32.4% vs. 48%) were
reported less often. Furthermore, an onset of disease after
childhood was not found in the current study. An explan-
ation for this difference is that of the 50 patients in our initial
1994 study, only 31 patients later proved to have mutations
in the MVK gene (22 of whom were also included in the
present study). Two patients were later diagnosed as having
TRAPS, 5 patients had a normal MVK gene upon testing,
while in the remaining 12 patients, the clinical diagnosis of
HIDS could not be confirmed at the molecular level because
of a lack of biological material.
Our data indicate that HIDS is a difficult diagnosis to
make. We found a median delay to diagnosis of 9.9 years
after onset of symptoms. Although genetic testing has been
available since the end of the last millennium, there con-
tinued to be a long delay to diagnosis in patients who were
diagnosed after the year 2000. Furthermore, in many patients
an alternative diagnosis was offered before the correct diag-
nosis of HIDS.
Aphthous ulcers can be a prominent feature in HIDS
patients. These can be restricted to the oral cavity but can also
include genital ulcers. Recently, in a genetic analysis of 96
patients who had a clinical diagnosis of Beh0et disease,
mutations in the MVK gene were found in 2 patients. Both
patients had clinical characteristics of HIDS including
recurrent fever attacks and arthralgia21. In our cohort, a diag-
nosis of Beh0et disease was made in 3 patients who ulti-
mately proved to have HIDS. Twelve patients had previously
been diagnosed with FMF. HIDS can be distinguished from
FMF on several grounds. First, FMF is rare in patients from
other than Mediterranean or Jewish ancestry35. Furthermore,
lymphadenopathy and aphthous ulcers, both important
features of HIDS, do not accompany attacks in FMF36. In
addition, HIDS does not respond to treatment with colchi-
cine. Although raised IgD concentrations have been
described in FMF patients, that is infrequent, and IgD
concentrations rarely exceed 200 IU/L23.
Elevation of IgD may provide a clue to the diagnosis,
but it is not diagnostic. Although the majority of patients
have an elevated IgD concentration, in 22% of patients IgD
values were normal. This is in line with other observa-
tions1,9,19,29. Furthermore, an elevation in serum IgD has
been described in other autoinflammatory diseases10,26.
TABLE 7. Mean Scores and SD Between Patients With HIDS
and Comparison Group on 2 Scales of the Course
of Life Questionnaire
HIDS
(n = 14)
Comparison Group
(n = 501) p Value
Social development
Mean 19.17 20.96 p = .01
SD 3.07 2.48
Autonomy development
Mean 8.31 9.87 p G 0.01
SD 1.18 1.48
TABLE 8. Clinical Guideline for When to Consider Testing
for HIDS
Consider testing for HIDS if patient has
Recurrent fever episodes lasting 3Y7 days persisting more than
6 months
AND 1 or more of the following:
1. Sibling with genetically confirmed HIDS
2. Elevated serum IgD (9100 IU/L)
3. First attack after childhood vaccination
4. Three or more of the following symptoms during attacks:
& Cervical lymphadenopathy
& Abdominal pain
& Vomiting or diarrhea
& Arthralgia or arthritis of large peripheral joints
& Aphthous ulcers
& Skin lesions
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In addition, we have previously found that IgD levels do
not correlate with inflammatory symptoms30.
This suggests that IgD should not be a requirement for
diagnosis, but can assist in making the diagnosis. Based on
our experience, we suggest a set of clinical characteristics
that may serve as a guideline in the rational ordering of
genetic tests (Table 8). A diagnosis of HIDS should be
entertained in patients with the following:
Recurrent episodes of fever lasting 3Y7 days persisting
more than 6 months AND
Elevated serum IgD (9100 IU/L) or
Sibling with confirmed HIDS or
First recorded attack after childhood vaccination or
At least 3 of the following symptoms during attacks:
cervical lymphadenopathy, abdominal pain, vomiting
or diarrhea, arthralgia or arthritis of large peripheral
joints, aphthous ulcers, and skin lesions.
Applying these criteria to our cohort, all patients
would be identified. However, this suggested guideline has
not been tested yet for its discriminative power in unselected
patients presenting with recurrent fever.
In the current study we did not find a relationship
between the 4 most prevalent mutations and the severity of
the phenotype. A possible bias could be that we include in
the database only patients who have a HIDS phenotype,
therefore excluding patients with the most severe phenotype
associated with MVK mutations, that is, MVA. MVA is, in
addition to fever attacks, characterized by psychomotor
retardation, progressive cerebral ataxia, dysmorphic features,
and progressive visual impairment18. Mandey et al25 could
differentiate MVA and HIDS patients based on their geno-
type: MVA patients never possess a V377I allele. However,
in a patient group restricted to HIDS, Cuisset et al8 also
failed to find a genotype-phenotype relationship.
We observed a gradual decrease in the frequency of
attacks during a patient_s life, although after the age of
20 years, half the patients still had attacks at least every
other month.
Long-term complications in our patient cohort con-
sisted of renal amyloidosis (n = 3), joint contractures (n = 4),
and abdominal adhesions (n = 10). The occurrence of ad-
hesions in the absence of prior surgery indicates that the
abdominal pain in HIDS attacks may be due to sterile
peritonitis, analogous to that in other autoinflammatory
syndromes. The incidence of amyloidosis was remarkably
low compared to other periodic fever syndromes33,35.
Recent developments have improved the treatment of
HIDS. The data in this cohort indicate that it may be a
reasonable strategy first to try using prednisone in a patient
with HIDS, starting at the first signs of attack. When this is
ineffective or insufficient, treatment with a biological agent
should be considered. A dose of 100 mg anakinra or 25 mg
etanercept subcutaneously at the first signs of an attack has
recently shown beneficial effects in a number of case
reports2,3,6,34, although randomized trials are lacking. If
either anakinra or etanercept is not effective, a switch to the
other can be considered, since some patients have good
response to anakinra but not etanercept, and vice versa. In
mildly affected patients, simvastatin can safely be tried to
reduce the number of days of illness without side effects31,
although the present study highlights its limited efficacy.
There does not appear to be a role in the treatment of HIDS
for other immunosuppressive and immunomodulatory
agents, or for continuous antibiotics.
In the current study we show that HIDS adversely
influences several aspects of quality of life. Although patients
were capable of performing physical activities as measured by
a physical functioning scale, they did experience limitations in
daily activities due to their disease. Furthermore, HIDS has an
unfavorable effect on the social functioning of patients.
Buskila et al5 found similar results in a study on the quality
of life in FMF patients. Although Buskila and colleagues used
a different instrument to measure quality of life, they found a
negative effect on social functioning and independence.
It is known that parents of chronically ill children tend
to overprotect their sick children28. Chronic diseases in
children often increase their dependence on caregivers and
decrease the participation in peer and school activities33.
This may explain the impairment in social development and
in the development of autonomy we found. But since this
questionnaire was developed for and validated in adolescents
and young adults (aged 16Y30 yr), we could include only 14
patients in the analyses of these items. Although there is a
significant difference between patients and controls, we
should be cautious about drawing firm conclusions.
No less than 42.9% of patients indicated that HIDS
prolonged their school career, and 26.6% of patients were
unemployed. It cannot be inferred from these data whether
the lack of educational and occupational achievement might
result in part from neurocognitive impairment due to the
metabolic defect itself. In any case, the febrile attacks do
interfere with a normal school career, and if this can be
prevented by effective antiinflammatory therapy, educational
and social outcomes may improve.
The results of the present study of quality of life are
relevant to clinical practice. Knowledge about possible gaps
in the development in the course of life and about dimen-
sions of child development that are affected by HIDS en-
ables physicians to focus attention on these subjects, and to
offer counseling where necessary. For example, pediatri-
cians could help parents to stimulate and encourage the in-
dependence of their child.
In conclusion, HIDS is a severe disease that starts early
in life with lifelong recurrent attacks of fever accompanied by a
variety of symptoms, including lymphadenopathy, abdominal
pain, arthralgia, vomiting and diarrhea, skin lesions, and
aphthous ulcers. In the current series of 103 patients, we found
a considerable delay to diagnosis (median, 9.9 yr). There is a
gradual decrease in the number of attacks with increasing age,
although half the patients over 20 years of age continued to
have more than 6 attacks per year. Prednisone, anakinra, and
etanercept can be effective in some patients in reducing the
severity of attacks. HIDS adversely affects several aspects of
the quality of life and interferes with educational achievements
and employment status. Infrequent but severe complications of
HIDS include amyloidosis (2.9%), joint contractures (3.9%),
and abdominal adhesions (9.7%).
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